Anna B. Halpern - Concepedia

Author

Anna B. Halpern

University of Washington ORCID

Also Known As

A B Halpern, A. B. Halpern, A. Halpern, A.B. Halpern, Anna B Halpern, Anna B. Halpern, Anna Halpern

162

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

University of Washington Fred Hutch Cancer Center University of Washington Medical Center Royal North Shore Hospital Cleveland Clinic

About

Anna B. Halpern is an author at University of Washington specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	451
2	Health Sciences	4	4	333
3	Pathology	4	4	327
4	Public Health	1	1	25
5	Health Policy	1	1	25

Anna B. Halpern

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission? Daisuke Araki, Brent L. Wood, Megan Othus, Journal of Clinical Oncology	2015	385
Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia Yi Zhou, Megan Othus, Daisuke Araki, Leukemia Hematological MalignancyResidual DiseaseTransplantationPost-transplant QuantificationMedicine	2016	187
Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit Anna B. Halpern, Eva Culakova, Roland B. Walter, JAMA Oncology	2016	86
Age-related differences in disease characteristics and clinical outcomes in polycythemia vera Brady L. Stein, Santosh L. Saraf, Urszula Sobol, Leukemia & lymphoma/Leukemia and lymphoma Hematological MalignancyImmunohematologyThrombosisPolycythemia VeraOncology	2012	83
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms Anna B. Halpern, Megan Othus, Emily M. Huebner, Leukemia Phase 1/2Hematological MalignancyOncologyHematologyMyeloid Neoplasia	2018	49
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm Raffaele Palmieri, Megan Othus, Anna B. Halpern, Journal of Clinical Oncology	2020	49
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck Ezra E.W. Cohen, Anna B. Halpern, Kristen Kasza, Oral Oncology MedicinePathologyHead And Neck CancerClinical BenefitDermatology	2009	45
Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML) Utkarsh Acharya, Anna B. Halpern, Qian Wu, Journal of Drug Assessment	2018	39
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study Anna B. Halpern, Megan Othus, Emily M. Huebner, Leukemia Phase 1/2Hematological MalignancyOncologyMedicineHematology	2017	36
Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia Janghee Woo, Dae Ro Choi, Barry E. Storer, Haematologica	2019	33

Page 1